89 results about "Tumor formation" patented technology

The invention relates to the technical field of medicines and biology, in particular to a mouse EGFR (Epidermal Growth Factor Receptor) mutant lung adenocarcinoma cell line (EP Mus musculus) as well as preparation and application thereof. The invention provides an EP cell line ([EGFRE19delta (mutation); trp53 (deletion), EP] is derived from a lung adenocarcinoma model of a C57BL / 6 strain mouse, carries the most common EGFRE19del mutation in lung adenocarcinoma, is a first lung adenocarcinoma mouse cell line carrying EGFR mutation known in the world at present, has the in-vivo tumorigenesis ability of the C57BL / 6 strain mouse, and fills the blank of the mouse EGFR mutant cell line. The cell line provided by the invention has the background of EGFRE19del homozygous activation mutation and Trp53 homozygous deletion mutation, is sensitive to EGFR-TKI targeted therapy, can be used for in-situ tumor formation in subcutaneous and lung of an immune normal mouse C57BL / 6, and is suitable for immunotherapy and targeted therapy research of EGFR mutation lung adenocarcinoma.

The invention relates to the technical field of biology, in particular to application of ginseng-sourced fermented polysaccharide in preparation of a medicine for treating colitis-related colon cancer, the ginseng-sourced fermented polysaccharide is ginseng-sourced probiotic fermented polysaccharide GPS-F. The probiotic fermented polysaccharide GPS-F is prepared by fermenting a ginseng polysaccharide extract with a Lacnospiraceae bacterium L.B. Strain, and the ginseng polysaccharide extract is prepared by fermenting the ginseng polysaccharide extract with the Lacnospiraceae bacterium L.B. Strain. The obtained ginseng fermented polysaccharide has good biological activity of resisting colitis-related colon cancer, mainly inhibits formation of neutrophil extracellular trapping nets and recovers intestinal barriers, so that tumor formation is inhibited, and the purpose of preventing and treating colitis-related colon cancer is achieved. The compound has a good application prospect in preparation of medicines for preventing and treating the ulcerative colitis-related colon cancer, has important significance in treatment of the ulcerative colitis-related colon cancer, and can be further used for development of health-care products and related medicines.

The invention provides a construction method and application of a mouse gastric cancer spontaneous tumor model, and the construction method comprises the following steps: reducing or inhibiting the expression quantity of a TP53 gene and / or the activity of a P53 protein in a mouse body, and then giving a drug to the mouse for chemical induction to obtain the mouse gastric cancer spontaneous tumor model. Wherein the drug contains sodium nitrite and ethyl sarcosinate, and / or the drug contains an N-nitroso compound. According to the construction method of the mouse gastric cancer spontaneous tumor model, the construction of the C57 mouse gastric cancer spontaneous tumor model by using the NESS is proposed for the first time, and the tumor formation rate can reach 75% or above; the tumor formation period is short and is about 3-4 months, and the construction cost is low.

The invention belongs to the technical field of traditional Chinese medicines, provides an application of a pain and diarrhea essential prescription in preparation of medicines for preventing and treating ulcerative colitis-related colon cancer for the first time, and opens up a new application of the pain and diarrhea essential prescription. A large number of in-vivo and in-vitro experiments prove that the pain and diarrhea essential prescription can inhibit tumor formation by inhibiting tumor cell proliferation and promoting mitochondrial autophagy of colon cancer cells, so that the purpose of preventing and treating the ulcerative colitis related colon cancer is achieved, and the pain and diarrhea essential prescription has a good application prospect in the aspect of preparing the medicine for preventing and treating the ulcerative colitis related colon cancer and has a wide application prospect. The traditional Chinese medicine composition has important significance for treating colon cancer related to colitis.

The invention provides a mutant spinal glioma cell line. The H3K27M mutant type glioma cell line is successfully constructed, the constructed cell line has more excellent multiplication capacity, migration capacity, tumor formation capacity and drug resistance, the curative effect and potential side effects of drugs can be more comprehensively evaluated, the cell line can be used for in-vitro research on the biological function of H3K27M glioma and response to drug treatment, and the cell line can be applied to in-vitro research of the H3K27M mutant type glioma. Wide application prospects are realized.

The invention relates to the technical field of biological materials, in particular to a biocompatible method for synthesizing quantum dots from living cells, which comprises the following steps: in the living cell culture process, adding an organic selenium compound containing Se-Se or Se-S bonds into a culture medium, and incubating to obtain selenized cells; further culturing by using a culture medium containing a metal ion-glutathione complex to obtain quantum dots containing metal elements and Se elements; according to the method, the generation of an active selenium precursor with cytotoxicity, such as hydrogen selenide, is effectively avoided, and meanwhile, the outbreak of active oxygen species in cells is also avoided, so that high quantum dot synthesis efficiency is shown. In-vitro cell experiment results show that the cells are endowed with a fluorescent function and still maintain good cell viability, and the cell viability is maintained at 80% or above; in-vivo experiment results show that the fluorescent cells with the synthesized quantum dots have good proliferation, tumor formation, invasion and metastasis capabilities in vivo.

The invention discloses a monoclonal cell for expressing HPV (human papilloma virus) 18 type E6 protein and application of the monoclonal cell in construction of an HPV tumor animal model, and relates to the technical field of HPV tumor animal models. A monoclonal cell which can stably express target protein and is good in tumor formation effect is obtained through a limited dilution method and single cell imaging sorting identification, and after an animal model is inoculated with the medicine or vaccine composition, the medicine or vaccine composition has an obvious inhibition effect on tumors; an animal model can be induced to generate high-level humoral immunity, and high-level specific CD4 + T cell and CD8 + T cell immune response can be generated. Compared with a TC-1 cell, the monoclonal cell provided by the invention has more remarkable tumorigenicity and can better mediate the growth of tumors in animals. The monoclonal cell obtained by screening has a good application prospect in screening a pharmaceutical composition or a vaccine composition for preventing and / or treating HPV, and can be used for evaluating a therapeutic vaccine for targeting HPV18.

The invention discloses a construction method and application of an animal model for evaluating cardiotoxicity of antitumor drugs, sodium carboxymethyl cellulose (CMC-Na) with extremely low cost is adopted to replace matrigel, a tumor-bearing mouse model with high stability can be constructed at low cost, and experimental verification shows that 4T1 cells are resuspended by using a 0.7% CMC-Na solution, and the tumor formation rate of subcutaneous inoculation reaches gt; 95%. The tumor microenvironment-mediated cardiac injury critical period is accurately captured, and the constructed tumor-bearing mouse model is the optimal tumor-bearing mouse model for evaluating the cardiotoxicity of an antitumor drug (adriamycin) in the tumor microenvironment in the third week after the mouse has a 50mm < 3 > tumor.

The invention belongs to the technical field of bioengineering, particularly relates to the field of tumor animal model research, and particularly provides a primary in-situ hepatocellular carcinoma animal model and a construction method thereof, and the primary in-situ hepatocellular carcinoma animal model is characterized in that primary in-situ hepatocellular carcinoma is formed in an animal liver; the primary in-situ hepatocellular carcinoma is formed in a primary in-situ manner by introducing a gene-edited liver organ into an animal liver tissue. The innovative hepatocellular carcinoma model construction technology promotes the primary in-situ development of long liver organs after gene editing into hepatocellular carcinoma, not only is the preparation period shorter, but also the tumor formation efficiency is higher, the occurrence and development, pathological conditions and clinical drug response of liver cancer patients can be effectively simulated, the full simulation of the tumor microenvironment is realized, and the application prospect is wide. And the development and research of new drugs and new treatment methods can be better guided.

The invention discloses application of lncRNASEH1-AS1 as a target in preparation of a medicine for treating lung squamous cell carcinoma, and belongs to the technical field of biological medicine. The invention finds that the expression of the lncRNASEH1-AS1 in tissues, plasma and cell lines of a lung squamous cell carcinoma patient is higher than that of a control group of the lung squamous cell carcinoma patient. The lncRNASEH1-AS1 has clinical correlation with the tumor diameter of a lung squamous cell carcinoma patient. The results of CCK-8, clone formation, Transwell migration and invasion experiments show that after the lncRNASEH1-AS1 and the MCM7 are knocked down, the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells is weakened, and after the lncRNASEH1-AS1 is over-expressed, the inhibition of the MCM7 on the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells can be reversely knocked down. The result of a nude mouse subcutaneous tumor formation experiment shows that the tumor formation capability of the LUSC cells which stably knock down the lncRNASEH1-AS1 is weakened.

This invention relates to a method for constructing a mouse orthotopic model of highly aggregated glioblastoma, belonging to the fields of biomedicine and experimental animal model technology. Glioblastoma cells are resuspended in a composite carrier of a specific ratio of matrix gel and serum-free culture medium, and a low-temperature injection technique is used. Utilizing the thermosensitivity of matrix gel in the mouse intracranial environment (i.e., its phase transition from liquid to gel at a certain temperature), precise colonization and physical locking of tumor cells at target coordinate points are achieved. This method improves upon existing glioblastoma mouse orthotopic model construction techniques that suffer from tumor cell diffusion and loss, low tumor formation rate, irregular tumor morphology, large intragroup variability, and needle reflux due to low viscosity of the inoculation carrier. It provides a good disease model for subsequent screening or evaluation of anti-glioblastoma drugs.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

Provided are a tumor risk evaluation method and system. Specifically provided are a method and / or system for evaluating the correlation between a sample under test and a tumor formation risk and / or tumor tissue source. Methylation variation regions of various different cancers and specific methylation characteristic regions of various organs are captured by using DNA or RNA oligonucleotide sequences, the existence of tumor components (ctDNA) in blood cell-free DNA (cfDNA) is determined, and the correlation between the sample and the tumor tissue source is evaluated. Provided is a low-cost and high-accuracy method, which is conducive to accurately predicting and evaluating the risk of various cancers.

The invention discloses a traditional Chinese medicine composition for treating tumors. The invention belongs to the medical field of traditional Chinese medicine for treating tumors. The medicine consists of 21 traditional Chinese medicines such as artemisia anomala, pseudo-ginseng, pseudobulbus cremastrae seu pleiones, rhizoma paridis, dried alum, sal ammoniac and ground beeltle, and comprises plant medicines, mineral medicines and animal medicines. According to the theory that tumor formation is mostly caused by qi and blood stasis, phlegm-damp toxin and stagnation and accumulation and is essentially blood death, stubborn phlegm and rotten water, the traditional Chinese medicine composition is prepared by adopting the method of regulating qi, promoting blood circulation to remove blood stasis, softening hardness to dissipate stagnation, eliminating phlegm, dredging collaterals, clearing away heat and toxic materials, relieving pain, removing rotten water and inducing diuresis as well as strengthening body resistance to eliminate pathogenic factors according to the principle of syndrome differentiation and treatment of traditional Chinese medicine. The method is an empirical method gradually formed by continuous exploration in the practice process. The medicine has a treatment effect on tumors; the traditional Chinese medicine composition also has the effect of relieving and easing pain caused by tumors.

Provided are a tumor risk evaluation method and system. Specifically provided are a method and / or system for evaluating the correlation between a sample under test and a tumor formation risk and / or tumor tissue source. Methylation variation regions of various different cancers and specific methylation characteristic regions of various organs are captured by using DNA or RNA oligonucleotide sequences, the existence of tumor components (ctDNA) in blood cell-free DNA (cfDNA) is determined, and the correlation between the sample and the tumor tissue source is evaluated. Provided is a low-cost and high-accuracy method, which is conducive to accurately predicting and evaluating the risk of various cancers.

This invention provides a hypoxia-mediated mechanism of malignant tumor formation, a treatment simulation method, and a system, relating to the field of biomathematical modeling technology. The method includes: dividing the tumor into a core region and a peripheral region, defining the core differences between the two regions in their microenvironmental composition, and forming a conceptual interaction network; establishing a state variable system centered on the number of tumor cells, constructing a mathematical model integrating tumor core-periphery heterogeneity, hypoxia-mediated processes, and immunosuppression cycles; solving the mathematical model, calculating the changes of each state variable over time under different initial conditions or intervention parameters, and outputting simulation results characterizing tumor growth and the state of the immune microenvironment; this invention, through the multi-level regulation of cell proliferation, immunosuppression cycles, and angiogenesis signals by oxygen concentration gradients, more realistically reproduces the spatial heterogeneous growth dynamics of solid tumors in vivo, and simulates the formation and maintenance mechanism of a strong immunosuppressive state in the tumor core region.

The invention provides application of FOXL2 in preparation of a medicine for promoting differentiation or treating ovarian cancer. The FOXL2 action mechanism research with clearer and more complete evidence chain is carried out on the action of the FOXL2 in ovarian cancer, especially epithelial ovarian cancer by using large sample data, the effects of overexpression FOXL2 on tumor formation inhibition, differentiation promotion, metastasis inhibition and the like of ovarian cancer cells are effectively verified, and a new strategy is provided for treatment of ovarian cancer.

The invention relates to application of a composition in preparation of drugs for treating breast tumors. The composition is a composition of a substance for inhibiting PSMD14 gene expression and unsaturated fatty acid, the substance for inhibiting PSMD14 gene expression is a substance for reducing the PSMD14 gene expression quantity by using specific shRNA (short hairpin ribonucleic acid) of a PSMD14 gene, and the unsaturated fatty acid can be arachidonic acid. Experiments prove that by inhibiting the expression of the PSMD14 gene and combining with unsaturated fatty acid, the death of breast tumor cells can be promoted, the growth of tumors can be inhibited, and the tumor formation speed of mice can be delayed. The application shows that the growth of the TNBC transplanted tumor can be inhibited by reducing the content of the PSMD14, the growth of the TNBC transplanted tumor can be further inhibited after the unsaturated fatty acid is added, the PSMD14 can be used as a potential target spot for treating TNBC patients, and a new non-surgical treatment scheme is provided for treating breast tumors.

The invention discloses an application of a circRNA marker in diagnosis and treatment of colorectal cancer, the expression level of a circular RNA gene hsacirc0066801 in samples of patients with colorectal cancer and tumor cells is obviously improved, and the overexpression of the circular RNA hsacirc0066801 can obviously promote the proliferation, migration and invasion of the colorectal cancer cells. Meanwhile, knock-down of the hsacirc0066801 can significantly inhibit proliferation, migration and invasion of colorectal cancer cells, in addition, nude mouse tumor formation experiments prove that the tumor volume is significantly increased after overexpression of the hsacirc0066801, and is reduced after knock-down of the hsacirc0066801. Therefore, the hsacirc0066801 can be used as a potential molecular marker and is used as a target spot for clinical diagnosis and treatment of the colorectal cancer.

The invention relates to the field of biological medicines, in particular to application of fatty acid synthase (FASN) as a target spot in screening or preparing medicines for treating breast cancer, and particularly relates to targeted therapy for breast cancer stem cells (BCSCs). The invention discloses application of an FASN target spot in screening or preparing a medicine for treating breast cancer. Research finds that FASN is highly expressed in BCSCs, and stem cell characteristics of the BCSCs are maintained by activating a Wnt / beta-catenin pathway. By inhibiting the activity of FASN (such as using lansoprazole), the proliferation, self-renewal and tumor formation ability of BCSCs can be significantly reduced. The invention provides an FASN-based drug screening method and a drug composition, and provides a new strategy for breast cancer treatment.

The application provides a benzene [d] isoxazole compound and an application thereof. The compound has the structure shown in the following formula I. The benzene [d] isoxazole compound provided by the application can induce degradation of BET protein and / or GSPT1 protein, and has an anti-proliferation effect on cancer cells. Therefore, the compound and the composition provided by the application can be used for preparing a drug for treating or preventing tumor formation, inflammation, viral infection, cell proliferative disorder, autoimmune disease, sepsis and the like.

The present invention relates to a method of converting human fibroblasts into neural stem cells, and more particularly, to a conversion method through direct cross-differentiation of human fibroblasts into neural stem cells using a combination of Sendai virus, mRNA or miRNA of a stem cell-related factor, and a small molecule compound, and a use thereof. According to the present invention, since high-quality neural stem cells may be induced from human fibroblasts through direct cross-differentiation within a short period of time, it is possible to secure a sufficient amount of cells for cell therapy, and since there is no side effect of tumorigenesis, the present invention may be used as a cell therapeutic agent for brain diseases.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses a siRNA combination and application thereof, and relates to the technical field of biology, and the siRNA combination comprises one or more of a first siRNA, a second siRNA, a third siRNA, a fourth siRNA, a fifth siRNA, a sixth siRNA, a seventh siRNA, an eighth siRNA, a ninth siRNA and a tenth siRNA. According to the invention, 10 kinds of siRNAs are designed to silence and knock down HNF4alpha, so that the multiplication capacity of prostatic cancer stem cells is remarkably inhibited; in addition, knock-down of HNF4alpha significantly inhibits the tumor formation ability of prostatic cancer stem cells in mice, and inhibits the malignant degree of prostatic cancer tumors.

The invention belongs to the technical field of biology, and particularly relates to a construction method of a gastric adenocarcinoma model. The method comprises the following steps: enabling an Anxa10-Cre / + animal or a filial generation of the Anxa10-Cre / + animal to react with LSL-KrasG12D / +; the method comprises the following steps: breeding a Tp53 R172H / + animal or a filial generation of the Tp53 R172H / + animal to obtain LSL-KrasG12D / +; tp53 R172H / < + >; anxa < 10 >-Cre / + animal; the method comprises the following steps of: adding LSL-KrasG12D / +; tp53 R172H / < + >; and N-methyl-N-nitrosourea is applied to an Anxa10-Cre / + animal. According to the method, the tumor formation period is shortened (about 2.5 months), the tumor formation rate is improved (100%), and the pathological type of the obtained gastric adenocarcinoma model is determined as adenocarcinoma.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

The application provides an improved PDX model construction method and a reagent combination thereof, comprising a treatment method of patient tumor tissue after being separated from a body, an activation reagent during transplantation and mouse pretreatment, and the like. The method of the application can significantly shorten tumor formation days and improve tumor formation rate.

The invention discloses a mouse M2 type macrophage induction method and application, and aims to solve the technical problem that mouse tumor cells cannot grow into tumors in a mouse body due to the fact that the polarization degree of current mouse M2 type macrophages is very low in the induction process. S2, after the cells are recovered and cultured, performing planking and virus infection on the recovered and cultured cells; s3, after the cells are subjected to planking and virus infection, protein and medicine configuration is carried out; s4, after the protein and the medicine are prepared, RAW264.7 M2 polarization condition setting is carried out; and S5, after the polarization condition of the RAW264.7 M2 is set. Protein drugs such as IL4, IL13, IL10, M-CSF, AZM, SOD and DEX are exogenously added, and lentivirus is used for mediating macrophages to stably express IL-4R receptors, so that M2 polarization of the macrophages is finally greatly improved, and a foundation is laid for subsequent research on growth and tumor formation of human / mouse tumor cells in mice.

The invention discloses application of 3-bromo-1H-pyrrole-2, 5-diketone in preparation of a composition for treating esophageal squamous carcinoma, and is characterized in that the molecular formula of the 3-bromo-1H-pyrrole-2, 5-diketone is C4H2BrNO2, the molecular weight of the 3-bromo-1H-pyrrole-2, 5-diketone is 175.97, and the 3-bromo-1H-pyrrole-2, 5-diketone is derived from marine sponge Axinella brevista. The 3-bromo-1H-pyrrole-2, 5-diketone disclosed by the invention can effectively inhibit proliferation, migration, invasion and in-vivo tumor formation of esophageal squamous carcinoma cells, shows extremely low cytotoxicity, is remarkably superior to that of traditional chemotherapeutic drugs, and solves the technical problem that existing drugs for resisting esophageal squamous carcinoma are large in toxic and side effects.

The present invention provides a human dedifferentiated liposarcoma cell line and application, belonging to the technical field of functional cell lines. The present invention is the first to successfully extract a dedifferentiated liposarcoma cell line, named RP-LPS01, and the preservation number is CGMCC No.46013. The cell line RP-LPS01 can be stably propagated for 50 generations and still maintain amplification without obvious changes, and can be directly used for the construction of a dedifferentiated fat animal model. Compared with the liposarcoma cell lines currently available in the American Type Culture Collection (ATCC), the cell line RP-LPS01 has more obvious molecular and biological characteristics of dedifferentiated liposarcoma, and a fast tumor formation rate in vivo. The cell line RP-LPS01 fills the gap in the in vitro and in vivo liposarcoma model of dedifferentiated liposarcoma, and provides a basis for studying the molecular mechanism of retroperitoneal liposarcoma.